Jacobio Pharma doses first patient with Aurora A inhibitor JAB-2485 in phase 1/2a trial
Jacobio Pharma said that it has completed the first patient dosage of Aurora A inhibitor JAB-2485, its in-house R&D drug candidate, in a phase 1/2a clinical trial in advanced solid tumor patients in the US.
According to the Chinese biotech company, JAB-2485 is a selective small molecule Aurora A inhibitor. It is the third Aurora A inhibitor to have advanced into clinical stage in the US.
The clinical trial is expected to be independently completed by the clinical team of Jacobio Pharma.
The global multicenter study will involve 102 patients and is likely to be completed in August 2026.
Preclinical data of JAB-2485 showed that it is highly selective at cellular and biochemical levels.
Jacobio Pharma said that Aurora A’s inhibitory activity is a thousand times higher than that of Aurora B, and can possibly benefit patients having small cell lung cancer and triple-negative breast cancer.